Myriad Genetics Crescita futura

Future criteri di controllo 0/6

Myriad Genetics prevede che gli utili e i ricavi cresceranno rispettivamente di 53.8% e 5.4% all'anno. Si prevede che l'EPS crescerà di 70.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.9% in 3 anni.

Informazioni chiave

53.8%

Tasso di crescita degli utili

70.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	24.4%
Tasso di crescita dei ricavi	5.4%
Rendimento futuro del capitale proprio	4.9%
Copertura analitica	Good
Ultimo aggiornamento	07 May 2025

Aggiornamenti recenti sulla crescita futura

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26

Recent updates

Myriad Genetics: Significantly Undervalued With Profitability In Sight

May 02

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Mar 24 Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 16

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26

Myriad Genetics: Navigating Through A Setback

Jan 16

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Jan 08

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:MYGN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	945	-1	33	48	10
12/31/2026	882	-57	23	48	16
12/31/2025	812	-63	26	32	12
3/31/2025	831	-101	-36	-6	N/A
12/31/2024	838	-127	-38	-9	N/A
9/30/2024	824	-116	-107	-70	N/A
6/30/2024	802	-155	-141	-93	N/A
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	43	52	N/A
9/30/2019	835	-15	83	92	N/A
6/30/2019	851	5	75	84	N/A
3/31/2019	830	23	91	100	N/A
12/31/2018	796	26	N/A	105	N/A
9/30/2018	767	54	N/A	100	N/A
6/30/2018	744	133	N/A	116	N/A
3/31/2018	749	130	N/A	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A
3/31/2015	722	95	N/A	130	N/A
12/31/2014	725	110	N/A	112	N/A
9/30/2014	745	137	N/A	107	N/A
6/30/2014	778	176	N/A	190	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MYGN ( 5.4% all'anno) crescerà più lentamente rispetto al mercato US ( 8.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MYGN ( 5.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MYGN sarà basso tra 3 anni ( 4.9 %).

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/07 18:58
Prezzo dell'azione a fine giornata	2025/05/07 00:00
Guadagni	2025/03/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Myriad Genetics, Inc. è coperta da 41 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jack Meehan	Barclays
Derek Taller	Benchmark Company
Michael Ryskin	BofA Global Research

Myriad Genetics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Price target decreased by 9.9% to US$16.01

Price target decreased by 7.3% to US$16.69

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Recent updates

Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology

First quarter 2025 earnings released: US$0.001 loss per share (vs US$0.29 loss in 1Q 2024)

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Myriad Genetics: Significantly Undervalued With Profitability In Sight

Myriad Genetics, Inc. to Report Q1, 2025 Results on May 06, 2025

Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting

Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing

Price target decreased by 9.9% to US$16.01

Myriad Genetics, Inc., Annual General Meeting, Jun 05, 2025

Price target decreased by 7.3% to US$16.69

Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Myriad Genetics, Inc. Announces Chief Executive Officer Changes

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Myriad Genetics, Inc. Announces Management Changes

Full year 2024 earnings released

Price target decreased by 8.6% to US$19.41

Myriad Genetics, Inc. to Report Q4, 2024 Results on Feb 24, 2025

Price target decreased by 8.0% to US$19.54

Consensus EPS estimates fall by 11%

Myriad Genetics: Navigating Through A Setback

Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Price target decreased by 10% to US$21.40

Myriad Genetics Elects Mark S. Davis as New Board Member

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Insider recently sold US$321k worth of stock

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

New minor risk - Financial position

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024